How Pathkey.AI’s TrialKey Is Reshaping Clinical Trials with New Leadership

• TrialKey platform continues to accurately predict clinical trial outcomes and share price movements
• Integration of drug-level features enhances AI capabilities for drug discovery and repurposing
• Board renewal with Damon Rasheed as Executive Chairman and Paul Niardone as Non-Executive Director
• Financial discipline maintained with $334,000 cash and flexible funding via bitcoin holdings and loan facility